Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Organogenesis Holdings Inc (ORGO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ORGO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -48.7% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 571.39M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 3198318 | Beta 1.66 | 52 Weeks Range 2.17 - 6.71 | Updated Date 03/31/2025 |
52 Weeks Range 2.17 - 6.71 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.18% | Operating Margin (TTM) 8.07% |
Management Effectiveness
Return on Assets (TTM) 2.81% | Return on Equity (TTM) 0.26% |
Valuation
Trailing PE - | Forward PE 12.32 | Enterprise Value 577423216 | Price to Sales(TTM) 1.19 |
Enterprise Value 577423216 | Price to Sales(TTM) 1.19 | ||
Enterprise Value to Revenue 1.2 | Enterprise Value to EBITDA 36.63 | Shares Outstanding 126828000 | Shares Floating 55551973 |
Shares Outstanding 126828000 | Shares Floating 55551973 | ||
Percent Insiders 46.66 | Percent Institutions 49.76 |
Analyst Ratings
Rating 4.5 | Target Price 5 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Organogenesis Holdings Inc
Company Overview
History and Background
Organogenesis Holdings Inc. was founded in 1985. It is a leading regenerative medicine company focused on developing and commercializing solutions for advanced wound care and surgical and sports medicine. It went public via SPAC in 2018.
Core Business Areas
- Advanced Wound Care: Develops and commercializes a portfolio of products for the treatment of chronic and acute wounds, including diabetic foot ulcers, venous leg ulcers, and burns.
- Surgical & Sports Medicine: Develops and commercializes regenerative medicine products for soft tissue repair, including rotator cuff tears, ACL reconstruction, and cartilage regeneration.
Leadership and Structure
Gary S. Gillheeney, Sr. is the President and Chief Executive Officer. The company has a board of directors and operates through various departments including R&D, Manufacturing, Sales & Marketing, and Finance.
Top Products and Market Share
Key Offerings
- Apligraf: A bioengineered skin substitute used to treat diabetic foot ulcers and venous leg ulcers. Competitors include Integra LifeSciences (IART) and Mimedx Group (MDXG).
- Dermagraft: A cryopreserved human fibroblast-derived dermal substitute used to treat diabetic foot ulcers. Competitors include Integra LifeSciences (IART) and Mimedx Group (MDXG).
- PuraPly AM: An antimicrobial barrier matrix for wound management. Competitors include ACell, Inc. and Convatec Group PLC (CTEC).
Market Dynamics
Industry Overview
The regenerative medicine market is growing rapidly, driven by the increasing prevalence of chronic diseases, an aging population, and advancements in biotechnology. The wound care market is a significant component of this overall market.
Positioning
Organogenesis is a leading player in the advanced wound care and surgical & sports medicine markets, with a strong portfolio of bioengineered products. Its competitive advantages include its established market presence, proprietary technology, and clinical data.
Total Addressable Market (TAM)
The total addressable market is estimated to be in the billions of dollars, with significant growth potential. Organogenesis is well-positioned to capture a larger share of this market through continued product innovation and market expansion.
Upturn SWOT Analysis
Strengths
- Established market position in advanced wound care
- Proprietary technology and intellectual property
- Strong clinical data supporting product efficacy
- Extensive sales and marketing network
- Diverse product portfolio
Weaknesses
- High research and development costs
- Dependence on reimbursement from government and private payers
- Competition from larger medical device companies
- Risk of product liability claims
Opportunities
- Expanding into new geographic markets
- Developing new products and applications for existing technologies
- Acquiring complementary businesses or technologies
- Increasing awareness and adoption of regenerative medicine products
- Capitalizing on favorable regulatory trends
Threats
- Increased competition from existing and new players
- Changes in reimbursement policies
- Product recalls or safety concerns
- Economic downturns
- Technological obsolescence
Competitors and Market Share
Key Competitors
- IART
- MDXG
- BSX
- ABMD
Competitive Landscape
Organogenesis has a strong presence in specific wound care niches, but faces competition from larger, more diversified medical device companies. Its competitive advantage lies in its specialized product portfolio and clinical expertise.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Organogenesis has experienced significant growth in revenue over the past several years, driven by increasing demand for its advanced wound care and surgical & sports medicine products.
Future Projections: Future growth is expected to be driven by continued product innovation, market expansion, and strategic acquisitions.
Recent Initiatives: Recent initiatives include launching new products, expanding the sales force, and investing in research and development.
Summary
Organogenesis Holdings Inc. is a regenerative medicine company with a leading presence in advanced wound care. While it has shown revenue growth, profitability can be variable. The company's future depends on continued product innovation, market expansion, and managing competition from larger players. Reimbursement pressures and potential product liabilities remain key factors to monitor.
Similar Companies
- IART
- MDXG
- BSX
- ABMD
Sources and Disclaimers
Data Sources:
- Company filings, Market research reports, Analyst estimates
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Organogenesis Holdings Inc
Exchange NASDAQ | Headquaters Canton, MA, United States | ||
IPO Launch date 2017-01-05 | President, CEO, Chair of the Board Mr. Gary S. Gillheeney Sr. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 869 | Website https://organogenesis.com |
Full time employees 869 | Website https://organogenesis.com | ||
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds. It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications. In addition, the company develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.